Notably, we found that cells expressing CTLA-4, the first approved checkpoint blockade target, displayed a generally low frequency (<20%) in both CD4 and CD8 T cell populations in the tumor and peripheral blood across eight cancer types. The gene discussed is CD8A; the disease is neoplasm.